Galecto Inc., whose recent SEC reports identify the registrant as Damora Therapeutics, Inc. following Galecto's acquisition of privately held Damora Therapeutics in November 2025, files disclosures covering biotechnology corporate structure, governance, and equity compensation. Form 8-K reports document executive officer appointments and departures, related compensation arrangements, and changes in the registrant's independent registered public accounting firm.
Proxy materials describe board matters, executive compensation, equity-award information, pay-versus-performance data, shareholder voting items, and governance procedures. The filing record also reflects public-company reporting around Galecto/Damora corporate status and clinical-stage therapeutic development.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. reported new equity awards to its Chief Operating Officer, Sherwin Sattarzadeh. On January 5, 2026, he received 190,376 shares of common stock in the form of restricted stock units, granted at a price of $0 per share. These RSUs vest 25% on each anniversary of the grant date over four years, so the award is spread out to encourage continued service.
On the same date, he was also granted a stock option covering 444,209 shares of common stock with an exercise price of $21.82 per share. This option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, again conditioned on his continued service to Galecto.
Galecto, Inc. filed an initial insider ownership report for its Chief Operating Officer. The Form 3 identifies Sherwin Sattarzadeh as the company’s Chief Operating Officer and a reporting person under insider ownership rules. The filing states in the remarks that no securities are beneficially owned, meaning the officer reported holding no Galecto, Inc. common stock or derivative securities at the time of this initial statement.
Paramora Holding LLC filed a Schedule 13G reporting beneficial ownership of 120,473 shares of Galecto, Inc. common stock, equal to 7.5% of the class based on 1,597,321 shares outstanding as of December 29, 2025. Paramora has sole voting and sole dispositive power over these shares, with no shared voting or dispositive power.
The filing notes additional Galecto Series C Non-Voting Convertible Preferred Stock held by Paramora that could convert into common stock at a rate of 1,000 common shares per preferred share, but these potential shares are excluded from the reported ownership. Conversion is subject to stockholder approval under Nasdaq rules and a 4.99% Beneficial Ownership Limitation, which restricts how much common stock Paramora can hold upon conversion. The filing states the securities are not held for the purpose of changing or influencing control of Galecto.
Galecto, Inc. shareholder Paragon Therapeutics, Inc. reports beneficial ownership of 120,473 shares of Galecto common stock, representing 7.5% of the class. Paragon has sole power to vote and dispose of these shares, with no shared voting or dispositive power.
The 7.5% figure is based on 1,597,321 shares of Galecto common stock outstanding as of December 29, 2025. The filing notes that this stake excludes common shares issuable from Series C Non-Voting Convertible Preferred Stock, which would convert at a rate of 1,000 common shares per preferred share, subject to stockholder approval and a 4.99% Beneficial Ownership Limitation. Paragon certifies that the securities are not held for the purpose of changing or influencing control of Galecto.
Galecto, Inc. reported that it plans to meet with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. During these meetings, the company expects to use a corporate slide presentation that is included as Exhibit 99.1, titled “Corporate Presentation (January 2026). The information related to these meetings and the presentation is being furnished under Regulation FD, meaning it is not treated as filed for purposes of the Securities Exchange Act of 1934 and is not subject to the associated liability provisions or automatically incorporated into other securities law filings.
Galecto, Inc. reported new equity awards to Chief Medical Officer Hewes L. Becker. On January 5, 2026, Becker received 264,629 restricted stock units, each representing one share of Galecto common stock at settlement. These RSUs vest 25% on each anniversary of the grant date over four years, conditioned on continued service.
On the same date, Becker was granted a stock option covering 528,603 shares of common stock at an exercise price of $21.82 per share. The option vests 25% on January 5, 2027 and then in equal monthly installments through January 5, 2030, also subject to continued service. Following these grants, Becker directly holds 264,629 shares of common stock and options for 528,603 shares.
Galecto, Inc.’s Chief Medical Officer files an initial ownership report showing no holdings. Hewes L. Becker, the company’s Chief Medical Officer, submitted a Form 3 indicating that no securities of Galecto, Inc. are beneficially owned. The filing confirms his officer role and that this is an individual filing, with a remark explicitly stating that no securities are beneficially owned.
Galecto, Inc. reported two key developments. The company issued a warrant to Paramora Holding LLC on December 31, 2025 to purchase up to 628,302 shares of common stock at an exercise price of $23.01 per share, relying on a private offering exemption under Section 4(a)(2) of the Securities Act. The warrant is effective as of that date and expires 10 years later.
Galecto also appointed Sherwin Sattarzadeh as Chief Operating Officer, effective January 5, 2026. His offer letter provides a base salary of $540,000, a target annual bonus equal to 40% of base salary, severance protections that increase in connection with a sale event, and company-subsidized health coverage for up to 18 months in certain termination scenarios. As an inducement grant, he will receive 190,376 restricted stock units vesting over four years and options to purchase 444,209 shares vesting over four years.